Skip to main content
Adrian Senderowicz, MD, Oncology, Bethesda, MD

AdrianMSenderowiczMD

Oncology Bethesda, MD

Physician

Dr. Senderowicz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Senderowicz's full profile

Already have an account?

  • Office

    9406 Linden Ave
    Bethesda, MD 20814
    Phone+1 301-530-0892

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1990 - 1992
  • New York-Presbyterian/Queens
    New York-Presbyterian/QueensInternship, Internal Medicine, 1989 - 1990
  • University of Buenos Aires
    University of Buenos AiresClass of 1987

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1992 - 2025

Publications & Presentations

PubMed

Abstracts/Posters

  • Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor...
    Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or Add-on to Ruxolitinib, in Patients with Refractory or...
    Adrian Senderowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • New Compounds Targeting Epigenetics Show Promise in Lymphoma Patients
    New Compounds Targeting Epigenetics Show Promise in Lymphoma PatientsMarch 5th, 2018
  • Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 in Combination with Checkpoint Inhibitors
    Constellation Pharmaceuticals Announces Initiation of Phase 1b/2 Study of CPI-1205 in Combination with Checkpoint InhibitorsJanuary 16th, 2018
  • Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer
    Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate CancerDecember 12th, 2017
  • Join now to see all

Grant Support

  • Translational Effects Of Small Molecule Cell Cycle ModulNational Institute Of Dental &Craniofacial Research2003–2004
  • Antiproliferative Effects Of Small Molecules: Basic AndNational Institute Of Dental &Craniofacial Research2002–2004
  • Antiproliferative Effects Of Small MoleculesNational Institute Of Dental &Craniofacial Research2000–2003

Professional Memberships